Cancer Therapy
Data advance knowledge in cancer therapy research
Published in Blood Weekly, March 30th, 2006
Study 1: Recent research from the United States has reported that alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism.
"Alemtuzumab is a humanized IgG1 kappa antibody directed against CD52, a glycosyl-phosphatidylinositol linked cell-membrane protein of unknown function. Herein, we demonstrate that alemtuzumab promotes rapid death of chronic lymphocytic leukemia (CLL) cells in vitro, in a complement and accessory cell free system," wrote A.P. Mone and colleagues, The Ohio State...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2006-03-30)
More Articles from Blood Weekly
- Blood Banking
Premier's plasma and recombinant program helps hospitals acquire products in short supply - Blood Safety
HIV prevalence in donated blood reduced after enhanced education and selection process - Blood Safety
Repeat blood donors have lower transfusion-transmissible infections than new donors - Blood Safety
Transfusion-associated Trypanosoma cruzi transmission occurring in Mexican blood banks - Blood Safety
West Nile virus-associated self-reported symptoms do not predict infection in blood donors - Angiology
High-dose folic acid does not protect vascular endothelium from IR injury in humans - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
